Free insulin cannot cross the placenta but insulin complexed to anti-insuli
n antibodies has been demonstrated in cord blood. We studied whether antibo
dy-bound insulin in diabetic patients can evoke fetal macrosomia independen
tly of maternal metabolic control. In 457 non insulin-treated controls and
173 insulin-treated diabetic patients we measured 1187 anti-insulin antibod
y levels and maternal blood glucose, maternal fructosamine, cord blood insu
lin, cord blood C-peptide, cord blood fructosamine and amniotic fluid insul
in. Mean anti-insulin antibody levels in maternal blood and cord blood were
significantly higher in insulin treated diabetic patients (4.6 and 5.4 U/m
l) than in controls (1.8 and 1.7 U/ml) with maxima of 89.2 in maternal and
120.0 U/ml in cord blood, respectively. In insulin treated diabetic patient
s 16.6% (maternal blood) and 22% (cord blood) anti-insulin antibody levels
were above the 97th percentile. There was a high significant correlation be
tween maternal and cord blood antiinsulin antibodies (R = 0.987, P = < 0.00
01), but no correlation of anti-insulin antibodies with maternal (glucose,
fructosamine) or fetal (insulin, C-peptide, and fructosamine in cord blood,
amniotic fluid insulin) metabolic parameters. While maternal and fetal met
abolic parameters correlated with birth weight neither maternal nor cord bl
ood anti-insulin antibody levels correlated with birth weight. These findin
gs do not support the hypothesis that maternal anti-insulin antibodies inde
pendently influence fetal weight. (C) 1998 Elsevier Science Ireland Ltd. Al
l rights reserved.